Generali Asset Management SPA SGR Sells 5,827 Shares of IQVIA Holdings Inc. $IQV

Generali Asset Management SPA SGR reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 15.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,797 shares of the medical research company’s stock after selling 5,827 shares during the period. Generali Asset Management SPA SGR’s holdings in IQVIA were worth $6,040,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in IQV. True Wealth Design LLC raised its stake in shares of IQVIA by 17.0% in the 3rd quarter. True Wealth Design LLC now owns 653 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 95 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in IQVIA by 3.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 7,936 shares of the medical research company’s stock valued at $1,617,000 after purchasing an additional 282 shares during the last quarter. Merit Financial Group LLC raised its position in shares of IQVIA by 4.1% in the third quarter. Merit Financial Group LLC now owns 15,859 shares of the medical research company’s stock valued at $3,012,000 after purchasing an additional 623 shares during the period. Smith Salley Wealth Management lifted its stake in shares of IQVIA by 3.8% in the third quarter. Smith Salley Wealth Management now owns 12,784 shares of the medical research company’s stock worth $2,428,000 after buying an additional 473 shares during the last quarter. Finally, Sivia Capital Partners LLC boosted its holdings in shares of IQVIA by 17.1% during the 3rd quarter. Sivia Capital Partners LLC now owns 3,816 shares of the medical research company’s stock worth $725,000 after buying an additional 557 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.0%

IQVIA stock opened at $225.48 on Friday. The business has a 50 day moving average price of $222.00 and a two-hundred day moving average price of $197.19. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $234.29. The stock has a market cap of $38.40 billion, a price-to-earnings ratio of 30.93, a price-to-earnings-growth ratio of 2.29 and a beta of 1.37.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.IQVIA’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and lifted their target price for the stock from $195.00 to $235.00 in a report on Thursday, October 9th. Truist Financial reaffirmed a “buy” rating and issued a $265.00 price target (up from $235.00) on shares of IQVIA in a research report on Wednesday, October 29th. Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $195.00 to $225.00 in a research report on Tuesday, September 9th. Stifel Nicolaus raised their target price on IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, Robert W. Baird set a $258.00 price target on IQVIA and gave the stock an “outperform” rating in a report on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $243.19.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.